Pfizer (PFE) reported Q4 FY 2018 earnings of $0.64 per share (versus $0.62 in Q4 FY 2017), beating analysts’ consensus estimate of $0.63.
The company’s quarterly revenues amounted to $13.976 bln (+2.0% y/y), generally in line with analysts’ consensus estimate of $13.920 bln.
The company also issued downside guidance for FY 2019, projecting EPS of $2.82-2.92 (versus analysts’ consensus estimate of $3.04) and revenues of $52-54 bln (versus analysts’ consensus estimate of $54.31 bln).
PFE fell to $38.50 (-2.61%) in pre-market trading.